The Motley Fool·2025-04-29 19:19Core Viewpoint - Shares of Hims & Hers Health and LifeMD surged significantly after Novo Nordisk announced the distribution of its GLP-1 weight loss drug Wegovy through telehealth platforms, enhancing access for patients [1][2]. Group 1: Company Developments - Hims & Hers Health's stock increased by 24%, while LifeMD's stock rose by 34% as of 3:15 p.m. ET [1]. - Wegovy will be available through Hims & Hers starting at $599 per month, which includes 24/7 care, nutritional guidance, and ongoing clinical support [3]. - LifeMD offers Wegovy at a reduced self-pay cost of $499 per month, including convenient home delivery [3]. Group 2: Market Dynamics - The partnership with Novo Nordisk revives a key revenue driver for Hims & Hers, which previously benefited from a supply shortage of GLP-1 drugs by selling compounded versions [3]. - LifeMD's stock has been less volatile but has declined over the past year [4]. - Hims & Hers is the most recognized telehealth provider and is expected to benefit the most from the partnership due to its brand recognition and existing customer base [5]. Group 3: Financial Metrics - Hims & Hers trades at a high valuation of 53.7 times earnings and 4.6 times sales, which may be considered expensive [5]. - LifeMD trades at a much lower valuation of 1.2 times earnings, despite still operating at a loss, indicating potential for growth [5].